2-h postchallenge plasma glucose predicts cardiovascular events in patients with myocardial infarction without known diabetes mellitus

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Henareh, Loghman ^a   Agewall, Stefan ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CORONARY ARTERY BYPASS GRAFT; DEATH; DIABETES MELLITUS; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PROSPECTIVE STUDY; RECURRENT DISEASE; SMOKING; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; AGED, 80 AND OVER; ANGINA, UNSTABLE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHI-SQUARE DISTRIBUTION; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SMOKING; STROKE; SWEDEN; TIME FACTORS;

EID: 84864535182     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-93     Document Type: Article

References (38)

1. Henareh L, Berglund M, Agewall S. Should oral glucose tolerance test be a routine examination after a myocardial infarction?. Int J Cardiol 2004, 97(1):21-24. 10.1016/j.ijcard.2003.06.023, 15336801.
2. Conaway DG, O'Keefe JH, Reid KJ, Spertus J. Frequency of undiagnosed diabetes mellitus in patients with acute coronary syndrome. Am J Cardiol 2005, 96(3):363-365. 10.1016/j.amjcard.2005.03.076, 16054458.
3. Leiter LA, Ceriello A, Davidson JA, Hanefeld M, Monnier L, Owens DR, Tajima N, Tuomilehto J. Postprandial glucose regulation: new data and new implications. Clin Ther 2005, 27(Suppl B):S42-S56.
4. Henareh L, Jogestrand T, Agewall S. Glucose intolerance is associated with C-reactive protein and intima-media anatomy of the common carotid artery in patients with coronary heart disease. Diabet Med 2005, 22(9):1212-1217. 10.1111/j.1464-5491.2005.01577.x, 16108851.
5. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up. Diabetologia 1996, 39(12):1577-1583. 10.1007/s001250050617, 8960845.
6. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996, 19(3):257-267. 10.2337/diacare.19.3.257, 8742574.
7. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999, 84(5):489-497. 10.1161/01.RES.84.5.489, 10082470.
8. Crisby M, Kublickiene K, Henareh L, Agewall S. Circulating levels of autoantibodies to oxidized low-density lipoprotein and C-reactive protein levels correlate with endothelial function in resistance arteries in men with coronary heart disease. Heart Vessels 2009, 24(2):90-95. 10.1007/s00380-008-1089-y, 19337791.
9. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, et al. Universal definition of myocardial infarction. Circulation 2007, 116(22):2634-2653. 10.1161/CIRCULATIONAHA.107.187397, 17951284.
10. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(Suppl 1):S62-S69. 2797383, 20042775.
11. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. american society of echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 1989, 2(5):358-367.
12. Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, Cameron AJ, Dwyer T, Taylor HR, Tonkin AM, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the australian diabetes, obesity, and lifestyle study (AusDiab). Circulation 2007, 116(2):151-157. 10.1161/CIRCULATIONAHA.106.685628, 17576864.
13. Meigs JB, Nathan DM, D'Agostino RB, Wilson PW. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham offspring study. Diabetes Care 2002, 25(10):1845-1850. 10.2337/diacare.25.10.1845, 12351489.
14. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The funagata diabetes study. Diabetes care 1999, 22(6):920-924. 10.2337/diacare.22.6.920, 10372242.
15. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999, 354(9179):617-621. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria.
16. Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Ryden L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 2004, 25(22):1990-1997. 10.1016/j.ehj.2004.09.021, 15541834.
17. Tamita K, Katayama M, Takagi T, Akasaka T, Yamamuro A, Kaji S, Morioka S, Kihara Y. Impact of newly diagnosed abnormal glucose tolerance on long-term prognosis in patients with acute myocardial infarction. Circulation journal: official journal of the Japanese circulation society 2007, 71(6):834-841.
18. Qiao Q, Pyorala K, Pyorala M, Nissinen A, Lindstrom J, Tilvis R, Tuomilehto J. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 2002, 23(16):1267-1275. 10.1053/euhj.2001.3113, 12175663.
19. Kitada S, Otsuka Y, Kokubu N, Kasahara Y, Kataoka Y, Noguchi T, Goto Y, Kimura G, Nonogi H. Post-load hyperglycemia as an important predictor of long-term adverse cardiac events after acute myocardial infarction: a scientific study. Cardiovasc Diabetol 2010, 9:75. 10.1186/1475-2840-9-75, 2996353, 21070650.
20. Schinner S, Futh R, Kempf K, Martin S, Willenberg HS, Schott M, Dinh W, Scherbaum WA, Lankisch M. A progressive increase in cardiovascular risk assessed by coronary angiography in non-diabetic patients at sub-diabetic glucose levels. Cardiovasc Diabetol 2011, 10:56. 10.1186/1475-2840-10-56, 3142488, 21702911.
21. Henkel E, Kohler C, Temelkova-Kurktschiev T, Hanefeld M. Predictors of abnormal glucose tolerance in persons at risk of type 2 diabetes: the RIAD study. Dtsch Med Wochenschr 2002, 127(18):953-957. 10.1055/s-2002-26731, 11987015.
22. Chu CS, Lee KT, Cheng KH, Lee MY, Kuo HF, Lin TH, Su HM, Voon WC, Sheu SH, Lai WT. Postchallenge responses of nitrotyrosine and TNF-alpha during 75-g oral glucose tolerance test are associated with the presence of coronary artery diseases in patients with prediabetes. Cardiovasc Diabetol 2012, 11:21. 10.1186/1475-2840-11-21, 3316140, 22397368.
23. Henareh L, Lind B, Brodin LA, Agewall S. Disturbed glucose metabolism is associated with left ventricular dysfunction using tissue doppler imaging in patients with myocardial infarction. Clin Physiol Funct Imaging 2007, 27(1):60-66. 10.1111/j.1475-097X.2007.00717.x, 17204040.
24. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324(7329):71-86. 10.1136/bmj.324.7329.71, 64503, 11786451.
25. Metoprolol in acute myocardial infarction (MIAMI) A randomised placebo-controlled international trial. The MIAMI trial research group. Eur Heart J 1985, 6(3):199-226. Metoprolol in acute myocardial infarction (MIAMI).
26. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342(3):145-153.
27. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin survival study (4 S). Lancet 1994, 344(8934):1383-1389.
28. Al-Delaimy WK, Willett WC, Manson JE, Speizer FE, Hu FB. Smoking and mortality among women with type 2 diabetes: The nurses' health study cohort. Diabetes Care 2001, 24(12):2043-2048. 10.2337/diacare.24.12.2043, 11723080.
29. Fuller JH, Stevens LK, Wang SL. Risk factors for cardiovascular mortality and morbidity: the WHO mutinational study of vascular disease in diabetes. Diabetologia 2001, 44(Suppl 2):S54-S64.
30. Rimm EB, Chan J, Stampfer MJ, Colditz GA, Willett WC. Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. BMJ 1995, 310(6979):555-559. 10.1136/bmj.310.6979.555, 2548937, 7888928.
31. Manson JE, Ajani UA, Liu S, Nathan DM, Hennekens CH. A prospective study of cigarette smoking and the incidence of diabetes mellitus among US male physicians. Am J Med 2000, 109(7):538-542. 10.1016/S0002-9343(00)00568-4, 11063954.
32. Fagard RH, Nilsson PM. Smoking and diabetes--the double health hazard. Prim Care Diabetes 2009, 3(4):205-209. 10.1016/j.pcd.2009.09.003, 19875348.
33. Ceriello A, Bortolotti N, Motz E, Crescentini A, Lizzio S, Russo A, Tonutti L, Taboga C. Meal-generated oxidative stress in type 2 diabetic patients. Diabetes Care 1998, 21(9):1529-1533. 10.2337/diacare.21.9.1529, 9727904.
34. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 2001, 108(4):635-636. 209408, 11518739.
35. Tomiyama H, Kimura Y, Okazaki R, Kushiro T, Abe M, Kuwabara Y, Yoshida H, Kuwata S, Kinouchi T, Doba N. Close relationship of abnormal glucose tolerance with endothelial dysfunction in hypertension. Hypertension 2000, 36(2):245-249. 10.1161/01.HYP.36.2.245, 10948085.
36. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, Kugiyama K, Ogawa H, Yasue H. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999, 34(1):146-154. 10.1016/S0735-1097(99)00168-0, 10400004.
37. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001, 104(22):2673-2678. 10.1161/hc4601.099485, 11723017.
38. Haenni A, Andersson PE, Lind L, Berne C, Lithell H. Electrolyte changes and metabolic effects of lisinopril/bendrofluazide treatment. Results from a randomized, double-blind study with parallel groups. Am J Hypertens 1994, 7(7 Pt 1):615-622.